Drug Development at the Portfolio Level Is Important for Policy, Care Decisions and Human Protections

JAMA. 2017 Sep 19;318(11):1003-1004. doi: 10.1001/jama.2017.11502.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clinical Trials as Topic*
  • Drug Discovery*
  • Health Policy*
  • Humans
  • Patient Safety
  • United States